Quick answer
Dr. Mei Lin is a Medical Affairs and Evidence Writer for Asia-Pacific Region pharmaceutical intelligence editor on NovaPharmaNews, with 20 published articles covering NMPA regulatory actions, clinical development, and market-moving news. Dr. Mei Lin covers evidence generation, congress narratives, and medical communications strategy in APAC markets. Over 8 years, she has supported field medical teams in translating trial and real-world evidence into practical clinical positioning.
About Dr. Mei Lin
Dr. Mei Lin covers evidence generation, congress narratives, and medical communications strategy in APAC markets. Over 8 years, she has supported field medical teams in translating trial and real-world evidence into practical clinical positioning.
Coverage focus
Topics and beats Dr. covers across Asia-Pacific Region.
Explore related intelligence
Entity directories linked from this author's coverage.
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways
Articles by Dr. Mei Lin
Quiver Bioscience Receives NIH HEAL Initiative Grant for QV-2421 Chronic Pain Therapy Clinical Trials
Quiver Bioscience secures NIH HEAL Initiative funding to advance QV-2421, a Nav1.7 antisense therapy for chronic pain, through IND studies and human trials.
BioMarin's PALYNZIQ Receives FDA Approval for Adolescent PKU Patients 12 and Older
BioMarin announces FDA approval of PALYNZIQ for adolescents 12+ with phenylketonuria (PKU), expanding treatment options for rare genetic disorder patients.
a2 Milk Company Recalls Three Batches of a2 Platinum Infant Formula Due to Health Risk Concerns
a2 Milk Company voluntarily recalls three batches of a2 Platinum Premium USA infant formula for 0-12 months due to potential health risks to babies.
SAKIGAKE Designation Japan: Bispecific Antibodies for Leukemia Status 2026
This article delves into the SAKIGAKE Designation in Japan for bispecific antibodies, focusing on their potential to transform leukemia treatment by 2026.
Vector Science & Therapeutics Files Patent for Microneedle Catheter Platform for Cancer Drug Delivery
Vector Science & Therapeutics secures IP protection for novel microneedle catheter technology designed to deliver cancer drugs directly into tumors.
ImmunityBio Faces Securities Fraud Lawsuit Over Anktiva Off-Label Promotion After FDA Warning Letter
ImmunityBio hit with class action lawsuit after FDA determined company made false claims about Anktiva bladder cancer drug's capabilities beyond approved use.
COFEPRIS CAR-T therapies review: What You Need to Know
This article reviews COFEPRIS CAR-T therapies, focusing on their application in treating blood cancers and what patients need to know before considering treatment.
Newleos Begins Phase 1b Trial of NTX-2001 for Alcohol Use Disorder Treatment
Newleos doses first patient in Phase 1b study of NTX-2001, a TAAR1 partial agonist targeting alcohol use disorder, marking key development milestone.
SFDA Expedited Review Oncology: What You Need to Know
Learn how the SFDA's expedited review process is transforming oncology drug approvals, including insights on Keytruda and its impact on cancer care.
Adagrasib Phase 3 Trial Results: Key Insights on KRAS G12C NSCLC
The Phase 3 trial results of Adagrasib highlight its promising efficacy in treating KRAS G12C NSCLC, offering new hope for patients with this challenging cancer.
China NMPA Data Integrity: What Foreign Pharma Must Know for Approval
Understanding China NMPA data integrity is crucial for foreign pharmaceutical companies seeking approval for their drugs in the competitive Chinese market.
EU Clinical Trial Site Selection: Impact of New Qualification Requirements on Timelines
This article examines the implications of new qualification requirements on the timelines for clinical trial site selection in the EU, particularly for oncology drugs.
Radiotherapy in African Cancer Centers: Current Status & Expansion Plans 2024
This article discusses the advancements and expansion plans for radiotherapy in African cancer centers, highlighting the need for improved cancer treatment options.
Immunic Appoints Dr. Michael Panzara as Chief Medical Officer to Lead Vidofludimus Calcium Development
Immunic Inc. names multiple sclerosis drug development expert Dr. Michael Panzara as CMO to advance Vidofludimus Calcium through pivotal trials.
WuXi AppTec Reports 39.4% Revenue Growth in Q1 2026, Backlog Reaches RMB 59.77 Billion
WuXi AppTec delivers strong Q1 2026 results with 39.4% revenue growth and 71.7% profit increase, signaling robust pharmaceutical outsourcing demand.
Bispecific Antibodies in Hematological Malignancies: Teclistamab & Market Trends 2025
Teclistamab is revolutionizing treatment for hematological malignancies, with emerging market trends set to influence bispecific antibody therapies by 2025.
Market Analysis: FDA Approval Revnasiran and Hereditary ATTR Amyloidosis
This article analyzes the market dynamics following FDA approval of Revnasiran for hereditary ATTR amyloidosis, highlighting its significance in patient care.
PMDA Advances Japanese Pharmacopoeia and Medical Device Standards Development Through Enhanced Regulatory Science Framework
Japan's PMDA strengthens pharmaceutical and medical device standards through expanded regulatory science initiatives and Japanese Pharmacopoeia updates.
Amcor Opens $35M Healthcare Packaging Facility in Malaysia to Strengthen Southeast Asia Medical Supply Chain
Amcor invests $35M in advanced healthcare packaging facility in Malaysia, bringing sterile medical packaging capabilities to Southeast Asia market.
Sonorous Neurovascular Receives FDA 510(k) Clearance for BosCATH™ Neurovascular Catheter
Sonorous Neurovascular gains FDA 510(k) clearance for BosCATH™ catheter, advancing neurovascular intervention capabilities for complex cerebral procedures.
Frequently asked questions
Who writes NovaPharmaNews articles?
Each story is attributed to a named editor or analyst with a public author profile. Profiles list credentials, coverage focus, and every published article so readers and AI systems can verify expertise and trace claims to a accountable journalist.
How do I find more coverage from this author?
Scroll to the article archive on this page, or use the topic chips linked from the author’s specializations. The regional authors directory lists every active contributor in this edition.
How does author coverage connect to companies and pipeline data?
Articles link to company profiles, drug INN pages, clinical trials, and pipeline programs when entities are tagged. Use the intelligence spokes on each story or browse topic hubs from the author’s beat.